DFCM
ALZN icon

Dark Forest Capital Management’s Alzamend Neuro ALZN Stock Holding History

Dark Forest Capital Management’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8
Closed -$13K – 1126
2022
Q3 		$13K Buy
+8
New +$11K ﹤0.01% 688

Other funds holding ALZN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Dark Forest Capital Management's ALZN Position: Q4 2022 in Review

Dark Forest Capital Management sold out of Alzamend Neuro (ALZN) in Q4 2022, closing a stake of 8 shares — an estimated $13K sold.

Dark Forest Capital Management first reported a position in ALZN in Q3 2022 and held it in 1 quarter. The position peaked at $13K in Q3 2022. 31 funds tracked by Wall St. Rank hold ALZN as of Q4 2022.

  • Dark Forest Capital Management reported no remaining Alzamend Neuro position as of Q4 2022 after selling out during the quarter.
  • Dark Forest Capital Management sold 8 Alzamend Neuro shares in Q4 2022, an estimated $13K.
  • Dark Forest Capital Management first reported a position in Alzamend Neuro in Q3 2022 and held it in 1 quarter.
  • Dark Forest Capital Management's Alzamend Neuro position peaked at $13K in Q3 2022.
  • 31 funds tracked by Wall St. Rank held Alzamend Neuro as of Q4 2022.

Based on Dark Forest Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.